Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.91
-0.08 (-1.14%)
At close: Feb 13, 2026, 4:00 PM EST
7.00
+0.09 (1.30%)
After-hours: Feb 13, 2026, 5:29 PM EST

Aligos Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
4314850415061,054
Market Cap Growth
-51.74%197.20%21.95%-91.94%-52.00%-
Enterprise Value
-5182-9-882761,180
Last Close Price
6.9139.8416.6023.82296.75691.25
PS Ratio
23.1337.483.202.93116.05-
PB Ratio
0.59-5.100.540.392.744.79
P/TBV Ratio
0.59-0.540.392.744.79
EV/Sales Ratio
-20.81--63.34-
Debt / Equity Ratio
0.08-0.290.120.120.080.06
Net Debt / Equity Ratio
-1.291.68-1.35-1.09-0.95-1.05
Net Debt / EBITDA Ratio
1.080.551.451.191.412.42
Net Debt / FCF Ratio
1.170.601.581.411.513.02
Asset Turnover
0.030.040.100.070.02-
Quick Ratio
4.512.625.683.804.908.04
Current Ratio
4.702.865.904.035.258.26
Return on Equity (ROE)
-141.82%-415.84%-89.48%-66.55%-63.41%-64.37%
Return on Assets (ROA)
-54.70%-50.29%-36.63%-31.92%-32.04%-29.70%
Return on Capital Employed (ROCE)
-98.80%-184.40%-68.50%-85.90%-65.30%-41.60%
Earnings Yield
-203.34%-88.73%-176.22%-235.41%-25.37%-10.30%
FCF Yield
-187.05%-54.69%-158.81%-196.90%-23.04%-7.24%
Buyback Yield / Dilution
-48.60%-144.38%-50.10%-7.12%-299.03%-397.63%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q